Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
CanadaIPO:
13 March 2015Website:
http://www.essapharma.comNext earnings report:
12 December 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 21 Nov 2024 00:54:21 GMTDividend
Analysts recommendations
Institutional Ownership
EPIX Latest News
NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens.
NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens.
NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens.
NEW YORK, NY / ACCESSWIRE / November 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens.
NEW YORK CITY, NY / ACCESSWIRE / November 3, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ:EPIX). Investors who purchased ESSA securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/EPIX.
NEW YORK CITY, NY / ACCESSWIRE / November 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ESSA Pharma Inc. ("ESSA" or "the Company") (NASDAQ:EPIX). Investors who purchased ESSA securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/EPIX.
What type of business is ESSA Pharma?
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
What sector is ESSA Pharma in?
ESSA Pharma is in the Healthcare sector
What industry is ESSA Pharma in?
ESSA Pharma is in the Biotechnology industry
What country is ESSA Pharma from?
ESSA Pharma is headquartered in Canada
When did ESSA Pharma go public?
ESSA Pharma initial public offering (IPO) was on 13 March 2015
What is ESSA Pharma website?
https://www.essapharma.com
Is ESSA Pharma in the S&P 500?
No, ESSA Pharma is not included in the S&P 500 index
Is ESSA Pharma in the NASDAQ 100?
No, ESSA Pharma is not included in the NASDAQ 100 index
Is ESSA Pharma in the Dow Jones?
No, ESSA Pharma is not included in the Dow Jones index
When was ESSA Pharma the previous earnings report?
No data
When does ESSA Pharma earnings report?
The next expected earnings date for ESSA Pharma is 12 December 2024